Anti-herpes viruses agents

Indian Journal of Pediatrics

Volumn 68, Issue 7, 2001, Pages 649-654

  Abdel Haq, Nahed M ^a   Asmar, Basim I ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Antiviral agents; Herpes virus; Resistant strains

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; IDOXURIDINE; PENCICLOVIR; TRIFLURIDINE; VALACICLOVIR; VIDARABINE;

BONE MARROW SUPPRESSION; CONFERENCE PAPER; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; NEUROTOXICITY; SIDE EFFECT; TREATMENT INDICATION; VARICELLA ZOSTER VIRUS;

EID: 0034886465     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02752280     Document Type: Conference Paper

References (37)

1. Prober CG. Antiviral agents and interferons. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice or Pediatic Infectious Diseases. New York; Churchill Livingstone. 1997 : 1682-1703.
2. Jacobson MA. Valacicolvir (BW 256U87) : the L-valyl ester of acyclovir. J Med Virol 1993; (Suppl) 1: 150-153.
3. Wagstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47 (1) : 153-205.
4. Whitley RJ, Alford AC, Hirsch MS et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314 (3) : 144-9.
5. Nyerges G, Meszner Z, Gyarmati E, Kerpel-Fronius S. Acyclovir prevents dissemination of varicella in imunocompromised children. J Infect Dis 1988; 157 (2) : 309-13.
6. Balfour HH Jr., Bean B, Laskin OL, Ambinder RF et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308 (24) : 1448-53.
7. Corey L, Benedetti J, Critchlow et al. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir : results of topical, intravenous and oral therapy. J Antimicrob Chemother 1983 (Suppl); 79-88.
8. Report of the Committee on Infectious Diseases. Red Book 2000 (25th edn.) American Academy of Pediatrics, Elk Grove Village, IL 2000.
9. Goldberg LH, Kaufman R, Kutz TO et al. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group. Arch Dermatol 1993; 129 (5) : 582-587.
10. Gold D, Corey L. Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother 1987 Mar; 31 (3) : 361-367.
11. Laskin OL, Longstreth JA, Whelton A et al. Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med 1982 73 (IA) : 197-201.
12. Revankar SG, Applegate AL, Markovitz DM. Delirium associated with acyclovir treatment in a patient with renal failure. Clin Infect Dis 1995 (2) : 435-436.
13. Rivaud E, Massiani MA, Vincent F, AzoulayE, Coudrec LJ. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient. Arch Intern Med 2000; 160 (11) : 1705-6.
14. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (altimore) 1997; 76 (5) : 369-380.
15. Brown ZA, Baker DA. Acyclovir therapy during pregnancy. Obstet Gynecol 1989; 73 (3) Pt 2) : 526-531.
16. Laufer DS, Starr SE. Resistance to antivirals. Pediatr Clin North Am 1995 42 (3) : 583-99.
17. Englund JA, Zimmerman ME, Swierkosz EM et al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care centre. Ann Intern Med 1990 15; 112 (6) : 416-422.
18. Grose C, Wiedeman J. Generic acyclovir vs. famciclovir and valacyclovir. Pediatr Infect Dis J 1997; 16 (9) : 838-841.
19. Fan-Havard P, Nahata MC, Brady MT. Ganciclovir-a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections. J Clin Pharm Ther 1989; 14 (5) : 329-340.
20. Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994 48 (3) : 455-484.
21. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109 (10) : 783-788.
22. Anders HJ, Goebel FD. Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome. Int J STD AIDS 1999; 10 (3) : 151-159, quiz 160-161.
23. Faqi AS, Klug A, Merker HJ, Chahoud I. Ganciclovir induces reproductive hazards in male rates after short-term exposure. Hum exp Toxicol 1997 16 (9) : 505-511.
24. Spector SA, Hsia K, Wolf D, Shinkai M, Smith I. Molecular detection of human cytomegalovirus and determination genotypic ganciclovir resistance in clinical specimens. Clin Infect Dis 1995; 21 Suppl 2: S170-173.
25. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999; 12 (2) 286-297.
26. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48 (2) : 199-226.
27. MacGregor RR, Graziani AL, Weiss R, Grunwald JE, Gambertioglio JG. Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. J Infect Dis 1991; 164 (4) : 785-787.
28. Deray G, Martinex F, Katlama C et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. An J Nephrol 1989; 9 (4) : 316-321.
29. Plosker GL, Noble S. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs 1999; 58 (2) : 325-345.
30. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36 (2) : 127-143.
31. Lalezari JP, Staff RJ, Kuppermann BD et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997 15; 126 (4) : 257-263.
32. Zabawski EJ Jr, Cockerell CJ. Topical and intralesional cidofovir : a review of pharmacology and therapeutic effects. J Am Acad Dermatol 1998; 39 (5 Pt 1) : 741-745.
33. De Smet MD, Meenken CJ, van den Horn GJ. Formivirsen-a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm 1999 Dec; 7 (3-4) : 189-198.
34. Galderisi U, Cascino A, Giordano A. Antisense oligonucleotides as therapeutic agents. J Cell Physiol 1999; 181 (2) : 251-7.
35. Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs 1982 May; 23 (5) : 329-353.
36. Denis J, Chouraqui P, Karpouzas I, Hoang-Xuan T, Pouliquen Y. Treatment of superficial herpes simplex keratitis with vidarabine (Vira A): multicenter study of 100 cases. J Fr Ophthalmol 1990; 13 (3) : 143-150.
37. De Clercq E. Antivirals for the treatment of herpes virus infections. J Antimicrob Chemother 1993; 32 (Suppl A) : 121-132.